Ginocchio Virginia Maria, Brunetti-Pierri Nicola
Telethon Institute of Genetics and Medicine, Pozzuoli (NA) 80078, Italy and.
Telethon Institute of Genetics and Medicine, Pozzuoli (NA) 80078, Italy and Department of Translational Medicine, Federico II University, Naples 80131, Italy
Hum Mol Genet. 2016 Apr 15;25(R1):R27-35. doi: 10.1093/hmg/ddv418. Epub 2015 Oct 6.
Because of their prevalence, severity and lack of effective treatments, inborn errors of metabolism need novel and more effective therapeutic approaches. The opportunity for an early treatment coming from expanded newborn screening has made this need even more urgent. To meet this demand, a growing number of novel treatments are entering in the phase of clinical development. Strategies to overcome the detrimental consequences of the enzyme deficiencies responsible for inborn errors of metabolism have been focused on multiple fronts at the levels of the gene, RNA, protein and whole cell. These strategies have been accomplished using a wide spectrum of approaches ranging from small molecules to enzyme replacement therapy, cell and gene therapy. The applications of new technologies in the field of inborn errors of metabolism, such as genome editing, RNA interference and cell reprogramming, along with progress in pre-existing strategies, such as gene therapy or cell transplantation, have tremendous potential for clinical translation.
由于先天性代谢缺陷的普遍性、严重性以及缺乏有效的治疗方法,需要新颖且更有效的治疗手段。扩大新生儿筛查带来的早期治疗机会使这一需求更为迫切。为满足这一需求,越来越多的新型治疗方法正进入临床开发阶段。克服导致先天性代谢缺陷的酶缺乏所产生的有害后果的策略已在基因、RNA、蛋白质和全细胞层面展开多方面研究。这些策略通过从小分子到酶替代疗法、细胞和基因疗法等广泛的方法得以实现。新技术在先天性代谢缺陷领域的应用,如基因组编辑、RNA干扰和细胞重编程,以及现有策略如基因治疗或细胞移植的进展,具有巨大的临床转化潜力。